Last reviewed · How we verify
NCT06711809
Sleep, Oxytocin and Reward Processing in Women in the Postpartum Phase
trial in Postpartum Depression in 100 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | International Research Training Group 2804 |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 January 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Sweden |
Conditions studied
- Postpartum Depression — all drugs for Postpartum Depression →
Sponsor
International Research Training Group 2804 — full company profile →
Who can join
18 and older, female only, with Postpartum Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
During and after pregnancy, a woman's body and brain undergo significant changes that help her adapt to caregiving and emotional needs. However, this period also makes women more susceptible to emotional disorders, such as peripartum depression (PPD), which affects about 10-15% of new mothers. PPD can negatively impact both the mother and her baby, disrupting mood, motivation, and mothering abilities. Hormonal changes and poor sleep are some of the risk factors that might worsen these depressive symptoms. Traditionally, sleep studies on PPD have relied on questionnaires and short-term sleep assessments. With the advent of smartwatches and digital devices, we can now monitor sleep in a home environment over longer periods. Oxytocin, a hormone crucial for childbirth, breastfeeding, and bonding with the baby, is thought to play a role in PPD. Studies suggest that higher levels of oxytocin might be linked to lower levels of postpartum depression, though findings are not always consistent. Oxytocin also affects sleep and is connected to brain areas that regulate reward and motivation. This study aims to explore the relationship between sleep, oxytocin, and reward processing in new mothers. The investigators will include women with varying levels of depressive symptoms and use home-based sleep assessments to gather data. Our goal is to better understand how these factors interact in the postpartum period and how they might influence a mother's mental health and caregiving abilities. The investigators expect that oxytocin levels are reduced in women with higher depressive symptoms and that these reductions are associated with sleep impairments, breastfeeding and altered reward processing.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06711809
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Postpartum Depression
Currently open trials in the same condition.
- NCT07398469 — A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone · recruiting
- NCT06442774 — MamaConecta: Digital Tool for Maternal Mental Health · NA · recruiting
- NCT06545760 — Admission to Kangaroo Mother Care (KMC) Ward and Maternal Postpartum Depression · NA · recruiting
- NCT05763537 — Understanding the Role of Doulas in Supporting People With PMADs · NA · recruiting
- NCT06462638 — COntact RElationship in Neonatal Intensive Care Unit · recruiting
Other International Research Training Group 2804 trials
Trials by the same sponsor.
- NCT06426459 — Social Media Usage in Adolescent Girls · not yet recruiting
- NCT06346457 — Breast Cancer & Antiestrogenic Therapy & Brain · unknown
- NCT06222749 — Oxytocin and Reward Processing in Women · NA · recruiting
- NCT06773429 — Estradiol and Brain Age · completed
- NCT06312033 — Estradiol's Effect on Brain Volume and Connectivity · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06711809 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by International Research Training Group 2804
- Last refreshed: 2 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06711809.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing